Latigo Biotherapeutics, Inc. (LTGO) stock
LTGONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026
$13.31−0.45 (-3.27%)
Close on Nov 18, 2026Market cap $882.44MP/E –Yield 0.00%
Latigo Biotherapeutics net income
Net income is the profit left for shareholders after every expense, interest and tax.
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$20.95M | – |
| Q2 FY2026 | Jun 30, 2026 | -$25.80M | – |
| Q1 FY2026 | Mar 31, 2026 | -$22.96M | – |
| Q3 FY2025 | Sep 30, 2025 | -$24.80M | – |
| Q2 FY2025 | Jun 30, 2025 | -$25.84M | – |
| Q1 FY2025 | Mar 31, 2025 | -$20.95M | – |
See a number that looks wrong?